However, except for selective CCR5 antagonists for HIV (Maraviroc) and a stem cell mobilizer (Mozobil), the promise of obtaining new therapeutics related to blocking chemokine receptor function in autoimmune diseases, inflammation, and cancer has not yet been realized. This evidence concerns the gene CCR5 and cancer.